Last reviewed · How we verify
Metoprolol succinate + doxazosin
This combination reduces blood pressure by blocking beta-adrenergic receptors (metoprolol) to decrease heart rate and cardiac output, while blocking alpha-1 adrenergic receptors (doxazosin) to relax blood vessels.
This combination reduces blood pressure by blocking beta-adrenergic receptors (metoprolol) to decrease heart rate and cardiac output, while blocking alpha-1 adrenergic receptors (doxazosin) to relax blood vessels. Used for Hypertension, Heart failure (metoprolol succinate component).
At a glance
| Generic name | Metoprolol succinate + doxazosin |
|---|---|
| Also known as | Toprol XL, Cardura, Carduran |
| Sponsor | University of Colorado, Denver |
| Drug class | Beta-blocker + Alpha-1 adrenergic antagonist combination |
| Target | Beta-1 adrenergic receptor; Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Metoprolol succinate is a beta-1 selective adrenergic antagonist that decreases heart rate, contractility, and blood pressure. Doxazosin is an alpha-1 adrenergic antagonist that causes vasodilation and reduces peripheral vascular resistance. Together, they provide complementary antihypertensive effects through different sympathetic nervous system pathways.
Approved indications
- Hypertension
- Heart failure (metoprolol succinate component)
Common side effects
- Dizziness
- Fatigue
- Hypotension
- Bradycardia
- Syncope
- Headache
Key clinical trials
- Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Black Education and Treatment of Hypertension (BEAT HTN) (PHASE4)
- Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metoprolol succinate + doxazosin CI brief — competitive landscape report
- Metoprolol succinate + doxazosin updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI